Form 4: Cytokinetics Director Executes Stock Option and Sells Shares

Wendall Wierenga, a director at Cytokinetics, exercised stock options and sold a portion of the acquired shares on November 25, 2024.

Summary

• On November 25, 2024, Wendall Wierenga, a director at Cytokinetics, exercised a non-qualified stock option to acquire 742 shares of common stock at a price of $7.37 per share.
• Following the exercise of the option, Mr. Wierenga sold 742 shares of Cytokinetics common stock at a price of $50 per share.
• After these transactions, Mr. Wierenga directly owns 24,559 shares of Cytokinetics common stock.
• The stock option was granted on February 2, 2015, and vested in monthly installments, becoming fully vested on January 2, 2016.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing a stock option exercise and share sale by a director. It doesn't indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, as mandated by the SEC.
• The transactions are typical for directors who receive stock options as part of their compensation.
• The sale of shares after exercising options is a common practice for insiders to realize gains.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider trading activity.
• The sale of shares by a director could have a minor impact on the stock price, but is unlikely to be significant.

Key Dates

Keywords

Cytokinetics, stock options, insider trading, Form 4, share sale, director, equity